Reduction of brain lipid peroxidation by CSF drainage in Alzheimer's disease patients

Journal of Alzheimer's Disease

Volumn 6, Issue 4, 2004, Pages 385-389

  Praticò, Domenico ^a   Yao, Yuemang ^a   Rokach, Joshua ^b   Mayo, Martha ^c,d   Silverberg, Gerald G ^e   McGuire, Dawn ^c,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Florida Institute of Technology   (United States)

^c Eunoe Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Isoprostanes; Oxidative stress

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; IMMUNOGLOBULIN G; ISOPROSTANE DERIVATIVE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CIRCULATION; BRAIN VENTRICLE PERITONEUM SHUNT; CELL COUNT; CEREBROSPINAL FLUID DRAINAGE; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 4644220088     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2004-6405     Document Type: Article

References (22)

1. D.A. Butterfield, A. Castegna, C.M. Lauderback and J. Drake, Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death, Neurobiol Aging 23 (2002), 655-664.
2. C.M. Clark, Clinical manifestation and diagnostic evaluation of patients with Alzheimer's disease, in: Neurodegenerative dementias: Clinical features and pathological mechanisms, C.M. Clark and J.Q. Trojanowski, eds, New York: McGraw-Hill, Inc., 2000, pp. 95-114.
3. D. Greitz and J. Hannerz, A proposed model of cerebrospinal fluid circulation: observations with radionuclide cisternography, Am. J. Neuroradiol. 17 (1996), 431-438.
4. S. Mattis, Mental status examination for organic mental syndrome in the elderly patient, in: Geriatric psychiatry, R. Bellack and B. Karasu, eds, New York: Grune and Stratton, 1976, pp. 77-121.
5. C. May, J.A. Kaye, J.R. Atack, M.B. Schapiro, R.P. Friedland and S.I. Rapoport, Cerebrospinal fluid production is reduced in healthy aging, Neurology 40 (1990), 500-503.
6. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price and E.M. Stadlan, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspice of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology 34 (1984), 939-944.
7. 2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls, Arch. Path. Lab. Med. 125 (2001), 510-512.
8. 2-isoprostanes in biological fluids and tissues as measure of oxidant stress, Meth. Enzymol. 300 (1999), 3-17.
9. H.E. Nelson, The National Adult Reading Test NART, Windsor, Canada: Nelson Publishing 1982.
10. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo, FASEB J 12 (1998), 1777-1783.
11. D. Praticò, J.A. Lawson, J. Rokach and G.A. Fitzgerald, The isoprostanes in biology and medicine, Trends Endocrinol. Metab. 12 (2001), 243-247.
12. 2α-VI in Alzheimer's disease: correlation of a non-invasive index of lipid peroxidation with disease severity, Ann. Neurol. 48 (2000), 809-812.
13. D. Praticò, Alzheimer's disease and oxygen radicals: new insights, Biochem. Pharmacol. 63 (2002), 563-567.
14. D. Praticò, C.M. Clark, F. Liun, J. Rokach, V.M-Y. Lee and J.Q. Trojanowski, Increased of brain oxidative stress in mild cognitive impairment. A possible predictor of Alzheimer's disease, Arch. Neurol. 59 (2002), 972-976.
15. D. Praticò, Oxidative imbalance and lipid peroxidation in Alzheimer's disease, Drug Dev. Res. 56 (2002), 446-451.
16. D. Praticò, Lipid peroxidation and the aging process, Science SAGE KE (2002), 50/re5.
17. E. Rubenstein, Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged, Lancet 351 (1998), 283-285.
18. G.D. Silverberg, G. Heit, S. Huhn, R.A. Jaffe, S.D. Chang, H. Bronte-Steward, E. Rubenstein, K. Possin and T.A. Saul, The cerebrospinal fluid production is reduced in dementia of the Alzheimer's type, Neurology 57 (2001), 1763-1766.
19. G.D. Silverberg, E. Levinthal, E.V. Sullivan, D.A. Bloch, S.D. Chang, J. Leverenz, S. Flitman, R. Winn, F. Marciano, T. Saul, S. Huhn, M. Mayo and D. McGuire, Assessment of low-flow CSF drainage as a treatment for AD. Results of a randomized pilot study, Neurology 59 (2002), 1139-1145.
20. S. Sisodia, Alzheimer's disease: perspectives for the new millennium, J. Clin. Invest. 104 (1999), 1169-1170.
21. M.A. Smith, C.A. Rottkamp, A. Nunomura, A.K. Raina and G. Perry, Oxidative stress in Alzheimer's disease, Biochim. Biophys. Acta 1502 (2000), 139-144.
22. 2α-VI differentiate AD from fronto-temporal dementia, Neurology 61 (2003), 475-478.